articl
summar
person
reflect
perspect
gener
practic
develop
regard
antibiot
resist
contain
antibiot
prescrib
lifetim
specialist
advisori
committe
antimicrobi
resist
england
reflect
concern
entri
antibiot
food
chain
recent
extens
prescrib
respons
develop
toward
improv
surveil
reduc
antibiot
prescrib
larg
gap
remain
scientif
appreci
risk
antimicrobi
resist
effect
mean
measur
therebi
hope
control
specialist
advisori
committe
antimicrobi
resist
sacar
set
follow
public
stand
medic
advisori
committe
report
invit
join
mainli
experi
diseas
surveil
commun
committe
approach
end
life
time
reflect
recent
develop
particularli
issu
concern
gener
practic
paper
circul
prior
initi
meet
committe
contain
two
surpris
firstli
uk
antibiot
given
anim
human
subsequ
report
health
protect
agenc
one
factor
influenc
develop
antibiot
resist
sinc
substanti
reduct
livestock
food
anim
total
quantiti
antibiot
given
chang
wherea
import
meat
meat
product
increas
substanti
like
contain
less
antibiot
thu
risk
associ
introduct
food
chain
increas
secondli
balanc
evid
belief
inappropri
prescrib
gener
practic
influenc
develop
antibiot
resist
inconclus
minor
except
public
fail
reach
definit
conclus
associ
two
difficulti
interpret
lie
wide
variat
patient
investig
laboratori
practic
within
countri
initi
govern
respons
three
key
element
strategi
identifi
name
surveil
prudent
antimicrobi
use
infect
control
carri
resourc
implic
sacar
perspect
seem
result
competit
fund
rather
develop
integr
packag
surveil
person
present
healthcar
close
complet
populationbas
surveil
realist
achiev
howev
valu
exist
inform
resist
avail
guid
gener
practition
remain
limit
difficult
interpret
limit
includ
lack
popul
denomin
bia
case
sampl
inadequ
distinct
communityand
hospitalacquir
infect
multipl
investig
patient
inconsist
record
inconsist
laboratori
procedur
individu
access
patientlink
data
need
surveil
earnestli
hope
establish
sacar
would
gener
momentum
would
lead
programm
structur
surveil
network
dedic
practic
link
limit
number
laboratori
aspect
record
report
problem
would
subject
continu
qualiti
control
result
integr
diseas
microbiolog
surveil
encourag
govern
respons
long
sinc
abandon
thought
could
achiev
ride
back
inform
gather
haphazardli
specimen
taken
part
routin
patient
manag
though
inform
gather
way
wast
except
offici
notifi
diseas
investig
nation
health
servic
nh
restrict
patient
person
case
manag
commun
protect
chief
argument
structur
surveil
primari
care
relat
percept
cost
thing
measur
much
cost
pay
pocket
come
major
cost
would
enhanc
microbiolog
investig
cost
enhanc
diseas
surveil
network
includ
routin
microbiolog
would
rel
small
sever
specif
project
complet
success
appropri
acknowledg
work
mcnulti
mant
mayonwhit
collabor
practic
gloucestershir
oxfordshir
chip
away
particular
problem
although
find
rare
generaliz
whole
countri
applic
later
time
period
problem
antimicrobi
resist
dynam
need
contemporari
data
virus
well
bacteria
respect
resist
pattern
virolog
investig
expens
even
less
part
routin
manag
primari
care
bacteriolog
investig
consist
record
essenti
order
monitor
trend
recogn
chang
current
systemat
approach
data
entri
gener
practic
record
standard
laboratori
comput
technolog
wherebi
practicebas
patient
record
updat
link
diagnost
prescrib
laboratori
data
one
episod
ill
extens
use
free
text
especi
relat
record
inform
minor
ill
milit
autom
investig
patient
record
qualiti
outcom
framework
could
perhap
exploit
achiev
highqual
standard
record
ensur
import
inform
enter
access
code
form
hidden
free
text
essenti
report
inform
diseas
prescript
miss
link
chang
time
clearli
expos
ensur
valid
interpret
analysi
trend
particular
care
need
interpret
base
chang
proport
rate
base
anyth
agespecif
popul
ethic
deliv
healthcar
focus
benefit
individu
public
health
less
import
mani
right
individu
champion
expens
right
societi
gener
person
use
facil
nh
inform
obtain
avail
manag
maxim
commun
health
individu
confidenti
paramount
surveil
purpos
patientspecif
inform
link
need
point
echo
govern
respons
patient
identif
surveil
greatli
hinder
recent
propos
allow
person
opt
nation
record
system
either
total
partial
implement
potenti
fulli
computer
record
diseas
surveil
never
fulli
realiz
critic
inform
withheld
exampl
part
routin
manag
drugresist
influenza
viru
isol
interpret
signific
requir
inform
individu
regard
comorbid
drug
exposur
record
inaccess
inadequ
purpos
inform
highli
import
public
health
lost
surveil
differ
research
requir
ethic
framework
prudent
prescrib
indefin
achiev
depend
knowledg
caus
organ
like
resist
pattern
clinic
signific
resistancewhich
may
influenc
mode
administr
eg
lowlevel
resist
may
matter
agent
appli
topic
result
high
local
concentr
relationship
resist
clinic
outcom
prescrib
guidelin
like
respect
evid
base
consensu
base
much
inform
deriv
research
inadequ
microbiolog
investig
evid
guidelin
minim
antibiot
resist
present
attitud
toward
prescrib
antimicrobi
excess
base
bacteri
caus
infect
reflect
lack
good
virolog
inform
howev
link
virolog
clinic
surveil
respiratori
infect
consider
enhanc
understand
influenzalik
ill
allow
us
least
ration
prescrib
antivir
particular
clinic
set
mani
doctor
believ
give
antibiot
might
good
least
cover
possibl
miss
diagnosi
signific
bacteri
diseas
littl
thought
given
possibl
harm
medic
train
improv
mani
doctor
still
see
viru
infect
minor
selflimit
therefor
sever
ill
bacteri
caus
consid
like
acut
bronchiti
elderli
particularli
associ
winter
excess
mortal
one
major
reason
prescript
antibiot
period
much
close
relat
winter
viral
epidem
diseas
long
caus
bronchiti
explain
scientif
way
improv
qualiti
prescrib
achiev
said
acut
otiti
media
though
increas
recognit
viral
aetiolog
mani
public
draw
attent
undesir
trend
toward
increas
use
newer
broadspectrum
antibiot
other
expos
downsid
inappropri
prescrib
howev
programm
medic
educ
target
reduc
prescrib
met
limit
success
use
delay
prescript
prescript
issu
recommend
dispens
unless
patient
improv
within
h
success
reduc
number
antibiot
dispens
though
increas
symptom
persever
except
trial
strategi
test
conduct
comprehens
bacteri
virolog
evalu
determin
prescript
appropri
intervent
appear
influenc
physician
prescrib
none
shown
effect
primari
object
reduc
antimicrobi
resist
success
intervent
reduc
prescrib
difficult
judg
acut
respiratori
infect
commonest
reason
prescrib
antibiot
much
less
frequent
year
ago
similar
trend
antibiot
prescrib
must
seen
background
contrast
diagnosi
skin
infect
use
topic
antibiot
skin
prepar
roughli
stabl
recent
year
yet
number
prescript
flucloxacillin
increas
similar
trend
observ
netherland
must
lull
fals
sens
secur
believ
prescrib
behaviour
gp
chang
prefer
focu
intervent
chang
behaviour
rather
tri
persuad
doctor
evid
link
resist
inappropri
prescrib
advanc
develop
nearpati
test
potenti
mix
bless
posit
side
accur
diagnosi
desir
individu
patient
manag
surveil
identif
pathogen
suffici
indic
antibiot
prescript
test
increas
consult
time
carri
signific
cost
often
disproportion
therapeut
benefit
nevertheless
potenti
valu
use
dedic
surveil
scheme
explor
sacar
discourag
extens
antibiot
prescrib
nurs
practition
move
permit
overthecount
use
recommend
endors
initi
govern
respons
select
extens
made
lifetim
committe
basi
believ
develop
antibiot
resist
acceler
whether
extens
describ
prudent
debat
recent
public
antimicrobi
resist
prefac
head
window
opportun
close
lack
new
antibiot
high
cost
develop
like
limit
market
may
serious
limit
option
control
infect
within
forese
futur
sacar
given
way
new
committe
remit
combin
issu
antibiot
resist
control
infect
hospit
equal
import
problem
view
merger
concern
fundament
need
reduc
inappropri
antibiot
prescrib
take
place
gener
practic
larger
combin
committe
like
margin
issu
reliabl
data
primari
care
put
back
still
introduct
scientif
base
surveil
programm
prescrib
ration
threat
pandem
influenza
domin
strateg
health
plan
threat
must
underestim
equal
vigour
need
context
emerg
antibiot
resist
wonder
along
other
yet
address
need
adequ
long
scientif
basi
first
measur
tackl
problem
transpar
declar
none
declar
